文献速递眼底病与葡萄膜炎

2024年内源性眼内炎病原学特征、临床表现与预后:单中心回顾性队列研究

[Etiological characteristics, clinical manifestations, and prognosis of patients with endogenous endophthalmitis in 2024: a single-center retrospective cohort study].
PubMed 文献 · Zhonghua Yan Ke Za Zhi · 2026-01-01

该单中心回顾性研究纳入2024年河南省立眼科医院33例(38只眼)内源性眼内炎患者,细菌感染占60.5%(以肺炎克雷伯菌为主),真菌感染占34.2%。所有患眼B超均显示较重玻璃体混浊,玻璃体切除术与视力改善相关(OR=0.068,95%CI:0.014~0.337,P=0.004)。

要点

  • 内源性眼内炎以细菌感染为主(60.5%),肺炎克雷伯菌最常见(34.2%)。
  • 真菌感染占34.2%,白色念珠菌最常见(13.2%)。
  • 玻璃体切除术可提高术后视力(OR=0.068,95%CI:0.014~0.337,P=0.004)。

核心结论

  • 2024年单中心资料表明内源性眼内炎以细菌感染为主,其次为真菌。
  • 患者玻璃体混浊较重,玻璃体切除术对预后视力提高至关重要。

研究设计与样本

  • 回顾性病例系列研究,纳入2024年1至12月河南省立眼科医院诊断并治疗的内源性眼内炎患者33例(38只眼)。
  • 所有患眼行最佳矫正视力、眼压和眼部B超检查,取房水或玻璃体标本行病原菌培养和(或)二代测序。
  • 所有患者接受全身抗菌药物治疗,根据情况行玻璃体注药术或(和)玻璃体切除术或眼内容物摘除联合义眼台植入术。
  • 采用Fisher精确概率检验或蒙特卡罗精确法进行统计分析,Logistic回归分析视力预后的影响因素。

主要发现

  • 38只患眼中23只眼(60.5%)为细菌感染,13只眼(34.2%)为真菌感染,2只眼(5.3%)为真菌与细菌混合感染。
  • 细菌感染中肺炎克雷伯菌13只眼(34.2%),金黄色葡萄球菌5只眼(13.2%),大肠埃希菌2只眼(5.3%)。
  • 真菌感染中白色念珠菌5只眼(13.2%),近平滑念珠菌2只眼(5.3%),烟曲霉菌2只眼(5.3%)。
  • 所有患者眼部B超显示均有较重的玻璃体混浊。
  • 纳入末次随访视力分析的33只眼中,22只眼(66.7%)视力提高,4只眼(12.1%)视力下降,7只眼(21.2%)视力无变化。

关键数值与推荐

  • 玻璃体切除术与术后视力提高相关(OR=0.068,95%CI:0.014~0.337,P=0.004)。
  • 3只眼(7.9%)行眼内容物摘除联合义眼台植入术,2只眼(5.3%)因全身情况不佳放弃治疗。

临床怎么用

  • 内源性眼内炎应尽早行病原学检测(培养和/或二代测序)以明确细菌或真菌感染。
  • 所有患者需全身抗菌药物治疗,并根据病情考虑玻璃体注药术或玻璃体切除术。
  • 玻璃体切除术可能有助于改善内源性眼内炎患者的最终视力。

局限性

  • 本研究为单中心回顾性病例系列,样本量有限(33例38只眼)。
  • 部分患眼病原学检测结果缺失或阴性,可能影响病原学特征分析。
  • 视力分析排除了放弃治疗的2只眼和行眼内容物摘除的3只眼。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the etiological characteristics, clinical manifestations, and prognosis of patients with endogenous endophthalmitis (EE). Methods: This was a retrospective case series study. Clinical data from patients diagnosed with EE and treated at Henan Eye Hospital between January 2024 and December 2024 were collected. Preoperative examinations included best-corrected visual acuity, intraocular pressure, and ocular B-ultrasound. The ocular status was evaluated using a slit-lamp biomicroscope and indirect ophthalmoscope. Samples of the aqueous humor and vitreous body were obtained for pathogenic bacterial culture or next-generation sequencing. Patients with previous etiological test results of blood or body fluids were included in the analysis. All patients received systemic antibiotic or antifungal treatment. Depending on disease severity, patients underwent intravitreal injection, pars plana vitrectomy (PPV), or evisceration with artificial eye socket implantation. Etiological characteristics, clinical manifestations, and treatment outcomes were assessed. Statistical analyses were performed using the Fisher's exact test or Monte Carlo exact method. The logistic regression analysis was applied to identify factors influencing the visual acuity improvement by calculating the odds ratio (OR) and its 95% confidence interval (95%CI). Results: A total of 38 eyes of 33 patients, 19 (57.6%) males and 14 (42.4%) females, diagnosed with EE were included. There were 16 cases (48.5%) in the right eye, 12 cases (36.4%) in the left eye, and 5 cases (15.1%) in both eyes. The age ranged from 22 to 80 years old, with a mean age of (59.5±13.0) years. Among the 38 affected eyes, 23 eyes (60.5%) had bacterial infections, including 13 eyes (34.2%) with Klebsiella pneumoniae, 5 eyes (13.2%) with Staphylococcus aureus, 2 eyes (5.3%) with Escherichia coli, 1 eye (2.6%) with Nocardia species, 1 eye (2.6%) with coinfection of Listeria monocytogenes and Enterobacter cloacae complex, and 1 eye (2.6%) with no available etiological test results. Thirteen eyes (34.2%) had fungal infections, including 5 eyes (13.2%) with Candida albicans, 2 eyes (5.3%) with Candida parapsilosis, 2 eyes (5.3%) with Aspergillus fumigatus, 1 eye (2.6%) with Fusarium species, 1 eye (2.6%) with Aspergillus flavus, 1 eye (2.6%) with Chaetomium globosum, and 1 eye (2.6%) with negative etiological test results in the vitreous humor. Two eyes (5.3%) had mixed fungal and bacterial infections. In all patients, ocular B-mode ultrasonography revealed severe vitreous opacity. Three eyes (7.9%) underwent evisceration combined with orbital implant placement. Treatment was discontinued for 2 eyes (5.3%) due to severe systemic conditions in the respective patients. The remaining 33 eyes (86.8%) were included in the visual acuity analysis at the last follow-up, of which 22 (66.7%) showed improved visual acuity, 4 (12.1%) had decreased visual acuity, and 7 (21.2%) had stable visual acuity. The logistic regression analysis revealed that PPV improved the final visual acuity (OR=0.068, 95%CI: 0.014-0.337, P=0.004). Conclusions: The single-center data from 2024 indicated that bacteria were the predominant pathogenic organisms of EE, followed by fungal species. Patients with EE exhibited severe vitreous opacity, and PPV played a crucial role in the visual prognosis. 目的: 探讨内源性眼内炎患者的病原学特征、临床表现和预后。 方法: 回顾性病例系列研究。纳入2024年1至12月在河南省立眼科医院诊断并治疗的内源性眼内炎患者的临床资料。所有患眼均行最佳矫正视力(BCVA)、眼压和眼部B超检查,并用裂隙灯显微镜和间接检眼镜观察眼部状况。取房水或玻璃体标本通过细菌、真菌培养和(或)二代测序(NGS)进行病原菌检测。将患者既往已行血液或体液病原菌检测的结果纳入分析。所有患者进行全身抗菌药物治疗;根据患者情况行玻璃体注药术或(和)玻璃体切除术或眼内容物摘除联合义眼台植入术。分析患者的感染菌种、临床表现、视力变化、治疗经过和预后。采用Fisher精确概率检验或蒙特卡罗精确法进行统计分析,并采用Logistic回归分析,通过计算比值比(OR)及其95%置信区间(95%CI)确定视力预后的影响因素。 结果: 共纳入患者33例(38只眼),其中男性19例(57.6%),女性14例(42.4%);右眼患病16例(48.5%),左眼患病12例(36.4%),双眼患病5例(15.1%);年龄为(59.5±13.0)岁。38只患眼中,23只眼(60.5%)为细菌感染,其中肺炎克雷伯菌13只眼(34.2%),金黄色葡萄球菌5只眼(13.2%),大肠埃希菌2只眼(5.3%),诺卡菌属1只眼(2.6%),单核细胞增生李斯特菌与阴沟肠杆菌复合群感染1只眼(2.6%),1只眼无病原菌检测结果(2.6%)。13只患眼(34.2%)为真菌感染,其中白色念珠菌5只眼(13.2%),近平滑肌念珠菌2只眼(5.3%),烟曲霉菌2只眼(5.3%),镰刀菌属1只眼(2.6%),黄曲霉菌1只眼(2.6%),球毛壳霉菌1只眼(2.6%);1只眼玻璃体液病原菌检测阴性(2.6%);2只眼(5.3%)为真菌与细菌混合感染。所有患者眼部B超显示均有较重的玻璃体混浊。38只患眼中,3只眼(7.9%)行内容物摘除联合义眼台植入术,2只眼(5.3%)因全身情况不佳放弃治疗,其余33只眼(86.4%)纳入末次随访视力分析。其中22只眼(66.7%)视力提高,4只眼(12.1%)视力下降,7只眼(21.2%)视力无变化。Logistic回归分析结果表明,行玻璃体切除术可提高患者术后视力(OR=0.068,95%CI:0.014~0.337,P=0.004)。 结论: 2024年单中心资料表明,内源性眼内炎患者以细菌感染为主,其次为真菌。患者玻璃体混浊较重,玻璃体切除术对其预后视力的提高至关重要。.

来源:Zhonghua Yan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li XL, Zhang XL, Han JJ, et al. [Etiological characteristics, clinical manifestations, and prognosis of patients with endogenous endophthalmitis in 2024: a single-center retrospective cohort study]. Zhonghua Yan Ke Za Zhi. 2026. PMID: 41491511. doi:10.3760/cma.j.cn112142-20250403-00170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。